Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.
Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, Walter RB, Wood BL, Roumier C, Philippé J, Denys B, Jorgensen JL, Bene MC, Lacombe F, Plesa A, Guzman ML, Wierzbowska A, Czyz A, Ngai LL, Schwarzer A, Bachas C, Cloos J, Subklewe M, Fuering-Buske M, Buccisano F. Tettero JM, et al. Among authors: cloos j. Hemasphere. 2021 Dec 22;6(1):e676. doi: 10.1097/HS9.0000000000000676. eCollection 2022 Jan. Hemasphere. 2021. PMID: 34964040 Free PMC article.
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.
Bachas C, Schuurhuis GJ, Hollink IH, Kwidama ZJ, Goemans BF, Zwaan CM, van den Heuvel-Eibrink MM, de Bont ES, Reinhardt D, Creutzig U, de Haas V, Assaraf YG, Kaspers GJ, Cloos J. Bachas C, et al. Among authors: cloos j. Blood. 2010 Oct 14;116(15):2752-8. doi: 10.1182/blood-2010-03-276519. Epub 2010 Jun 30. Blood. 2010. PMID: 20592250 Free article.
Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients.
Hanekamp D, Denys B, Kaspers GJL, Te Marvelde JG, Schuurhuis GJ, De Haas V, De Moerloose B, de Bont ES, Zwaan CM, de Jong A, Depreter B, Lammens T, Philippé J, Cloos J, van der Velden VHJ. Hanekamp D, et al. Among authors: cloos j. Br J Haematol. 2018 Nov;183(3):512-516. doi: 10.1111/bjh.14991. Epub 2017 Oct 26. Br J Haematol. 2018. PMID: 29076143 Free article. No abstract available.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Schuurhuis GJ, et al. Among authors: cloos j. Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Blood. 2018. PMID: 29330221 Free PMC article. Review.
Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.
Freeman SD, Hills RK, Russell NH; UK NCRI AML Trial Group; Cloos J, Kelder A, Ossenkoppele GJ, Schuurhuis GJ; HOVON AML Trial Group. Freeman SD, et al. Among authors: cloos j. Br J Haematol. 2019 Jul;186(1):130-133. doi: 10.1111/bjh.15698. Epub 2018 Dec 5. Br J Haematol. 2019. PMID: 30520018 Free article. No abstract available.
TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.
Depreter B, Weening KE, Vandepoele K, Essand M, De Moerloose B, Themeli M, Cloos J, Hanekamp D, Moors I, D'hont I, Denys B, Uyttebroeck A, Van Damme A, Dedeken L, Snauwaert S, Goetgeluk G, De Munter S, Kerre T, Vandekerckhove B, Lammens T, Philippé J. Depreter B, et al. Among authors: cloos j. Haematologica. 2020 May;105(5):1306-1316. doi: 10.3324/haematol.2019.222612. Epub 2019 Aug 1. Haematologica. 2020. PMID: 31371409 Free PMC article.
206 results